As a result, full-length coverage of FA genes and cancer-associated genes is not achievable, precluding reliable detection of pathogenic germline variants, secondary somatic mutations (e.g., in TP53), or complex cytogenetic abnormalities. This evidence concerns the gene TP53 and Friedreich ataxia.